WO2013126720A3 - Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing - Google Patents

Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing Download PDF

Info

Publication number
WO2013126720A3
WO2013126720A3 PCT/US2013/027347 US2013027347W WO2013126720A3 WO 2013126720 A3 WO2013126720 A3 WO 2013126720A3 US 2013027347 W US2013027347 W US 2013027347W WO 2013126720 A3 WO2013126720 A3 WO 2013126720A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
assessment
target cancer
cancer cell
Prior art date
Application number
PCT/US2013/027347
Other languages
French (fr)
Other versions
WO2013126720A2 (en
Inventor
Carl H. June
Yangbing Zhao
Shannon MCGETTIGAN
John Scholler
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2013126720A2 publication Critical patent/WO2013126720A2/en
Publication of WO2013126720A3 publication Critical patent/WO2013126720A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Abstract

The present invention relates to compositions and methods of using flow cytometry to assess the susceptibility cancer cells to various immunotherapies.
PCT/US2013/027347 2012-02-22 2013-02-22 Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing WO2013126720A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601898P 2012-02-22 2012-02-22
US61/601,898 2012-02-22

Publications (2)

Publication Number Publication Date
WO2013126720A2 WO2013126720A2 (en) 2013-08-29
WO2013126720A3 true WO2013126720A3 (en) 2015-06-11

Family

ID=49006369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/027347 WO2013126720A2 (en) 2012-02-22 2013-02-22 Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing

Country Status (1)

Country Link
WO (1) WO2013126720A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
JP6541639B2 (en) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Methods to control T cell proliferation
WO2015090230A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
AU2015218396A1 (en) * 2014-02-14 2016-08-11 Bellicum Pharmaceuticals, Inc. Methods for activating T cells using an inducible chimeric polypeptide
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3329282A4 (en) * 2015-07-31 2019-04-24 Dongfang Liu Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (car) t cells
CN107298715B (en) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D 2-chimeric antigen receptor and application thereof
CN106008721B (en) * 2016-08-09 2020-02-07 安徽未名细胞治疗有限公司 C-Met specific chimeric antigen receptor and application thereof
WO2018058432A1 (en) * 2016-09-28 2018-04-05 李华顺 Polygenic recombinant chimeric antigen receptor molecule and use thereof
MX2019011475A (en) 2017-03-31 2019-12-16 Cellectis Universal anti-cd22 chimeric antigen receptor engineered immune cells.
CN113766956B (en) 2019-03-05 2024-05-07 恩卡尔塔公司 CD 19-directed chimeric antigen receptor and use thereof in immunotherapy
EP4162269A1 (en) * 2020-06-08 2023-04-12 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
CN113109572A (en) * 2021-04-01 2021-07-13 苏州才博医学科技有限公司 Method for detecting somatic immunogenicity of autologous CART cells
CN116516007B (en) * 2023-04-18 2024-01-19 华中科技大学同济医学院附属协和医院 Method for detecting CD19 expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090990A2 (en) * 2004-01-23 2005-09-29 Sanofi Pasteur, Inc. Cytotoxicity assay
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US20120282256A1 (en) * 2003-11-05 2012-11-08 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282256A1 (en) * 2003-11-05 2012-11-08 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005090990A2 (en) * 2004-01-23 2005-09-29 Sanofi Pasteur, Inc. Cytotoxicity assay
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRKHOLZ ET AL.: "Transfer of mRNA encoding recombinant immunoreceptors reprograms CD 4+ and CD 8+ T cells for use in the adoptive immunotherapy of cancer.", GENE THERAPY, vol. 16, 2009, pages 596 - 604 *
PORTER ET AL.: "Chimeric Antigen Receptor Modified T Cells in Chronic Lymphoid Leukemia.", N ENGL J MED, vol. 365, 2011, pages 725 - 733, XP002732435, DOI: doi:10.1056/NEJMoa1103849 *

Also Published As

Publication number Publication date
WO2013126720A2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
WO2013126720A3 (en) Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
WO2015073990A8 (en) Compositions and methods of using transposons
IL236679A0 (en) Compositions and methods for regulating car t cells
EP3383411A4 (en) Methods and compositions relating to chondrisomes from cultured cells
IL240881A0 (en) T cell balance gene expression, compositions of matters and methods of use thereof
EP3313991A4 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
ZA201502884B (en) Compositions and methods for modulating cell signaling
IN2015DN00143A (en)
EP2904106A4 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
EP2971116A4 (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
EP3296402A3 (en) Methods and compositions for weed control
WO2014145232A3 (en) Methods and compositions for assessing renal status using urine cell free dna
IN2015DN00127A (en)
WO2011156654A3 (en) Pathways characterization of cells
EA201491574A1 (en) APPLICATION OF CAR, BASED ON ICOS, TO STRENGTHEN ANTI-TUMOR ACTIVITY AND LONG-TERM CAR SAVING
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
EP2935359A4 (en) Compositions with ph responsive copolymer containing maep and/or mahp and methods for using same
WO2014025958A3 (en) Treatment of immune-related and inflammatory diseases
WO2013188469A3 (en) Pathways characterization of cells
EP3697820A4 (en) Methods and compositions relating to engineered regulatory t cells
WO2014001229A3 (en) Cell penetrating peptides & methods of identifying cell penetrating peptides
WO2012135340A3 (en) Compositions and methods for diagnosing cancer
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13752034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13752034

Country of ref document: EP

Kind code of ref document: A2